Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 52Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Stomach Neoplasms 10Neoplasms 9Parkinson Disease 4, Autosomal Dominant Lewy Body 8Urinary Bladder Neoplasms 6Neoplasm Metastasis 6Head and Neck Neoplasms 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Nasopharyngeal Carcinoma 3Laryngeal Neoplasms 3HER2-positive Breast Cancer 3Fallopian Tube Neoplasms 3Esophageal Squamous Cell Carcinoma 3Carcinoma 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Vaccinia 2

Interventions

Cisplatin 14Paclitaxel 12pembrolizumab 9Fluorouracil 7Radiotherapy 6Irinotecan 5Esophagectomy 5tislelizumab 4Oxaliplatin 4Leucovorin 4Drug Therapy 4Carboplatin 4toripalimab 3Levoleucovorin 3Docetaxel 3Capecitabine 3camrelizumab 2Taxes 2Radiation 2Nivolumab 2Injections 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1palbociclib 1nimotuzumab 1nazartinib 1lenvatinib 1ivarmacitinib 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × Docetaxel × 90 days × Clear all
NCT07621601 2026-06-02

A Study of HS-20093 in Patients With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)

Hansoh BioMedical R&D Company

Phase 3 Not yet recruiting
494 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

NCT07463573 2026-04-24

QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 3 Recruiting
466 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06304974 2026-04-17

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 3 Active not recruiting
497 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡